Completed PHASE3 INTERVENTIONAL 2-arm NCT03278600

Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary

The Value of Tissue-of-origin (ORIGIN-PanCA○R) Profiling in Predicting Primary Site and Directing Therapy in Patients With Cancer of Unknown Primary: a Prospective Randomized Controlled Study

Sponsor: Fudan University

Conditions Cancer of Unknown Primary Site

Interventions tissue-of-origin (ORIGIN-PanCA○R) profiling

Updated 8 times since 2017 Last updated: Jan 21, 2022 Started: Sep 18, 2017 Primary completion: Mar 18, 2021 Completion: Mar 18, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03278600, this PHASE3 trial focuses on Cancer of Unknown Primary Site and remains completed. Sponsored by Fudan University, it has been updated 8 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2022 — Jul 2024 [monthly]

Completed PHASE3
Apr 2021 — Feb 2022 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE3

▶ Show 3 earlier versions

Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE3
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE3
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China